Henry Schein (HSIC) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
8 Jul, 2026Executive summary
Achieved record Q3 2025 results with 5.2% sales growth, non-GAAP EPS up 13.1% to $1.38, and GAAP EPS up to $0.84, with all segments contributing and notable market share gains in distribution and technology.
Raised 2025 non-GAAP diluted EPS guidance to $4.88–$4.96 and total sales growth to 3–4%, reflecting strong Q3 results and a $28 million remeasurement gain.
Value creation initiatives are expected to deliver over $200 million in operating income improvements over the next few years.
Board approved KKR's right to increase stock ownership up to 19.9% and a $750 million increase in share repurchase authorization.
Continued strategic investments, including a phased rollout of a new global eCommerce platform and partnership with Amazon Web Services for generative AI integration.
Financial highlights
Q3 2025 global sales reached $3.34 billion, up 5.2% year-over-year, with 4.0% constant currency growth and 0.7% from acquisitions.
Q3 2025 GAAP net income was $101 million ($0.84 per diluted share); non-GAAP net income was $167 million ($1.38 per diluted share).
Adjusted EBITDA for Q3 2025 was $295 million, up 10% year-over-year.
Operating cash flow for Q3 2025 was $174 million; year-to-date operating cash flow was $644 million.
Gross margin for Q3 2025 was 30.7%, down 56 bps year-over-year, mainly due to product mix.
Outlook and guidance
2025 non-GAAP diluted EPS guidance raised to $4.88–$4.96, with total sales growth expected at 3–4% over 2024 and adjusted EBITDA to grow mid-single digits.
Full-year non-GAAP effective tax rate expected at 24%–25%.
Guidance assumes stable FX rates and mitigated tariff effects.
The 2024 restructuring plan is expected to continue through 2027, with further charges anticipated.
Company expects to benefit from OBBBA tax changes, reducing current income tax liabilities.
Latest events from Henry Schein
- Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 20248 Jul 2026 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 20248 Jul 2026 - Strategic initiatives and value creation projects drive stable growth and operational efficiency.HSIC
Baird Global Healthcare Conference 20258 Jul 2026 - Transformation, innovation, and disciplined growth drive strong outlook and value creation.HSIC
Stifel Jaws & Paws Conference 202627 May 2026 - Leadership changes, all proposals passed, and majority voting adopted for future governance.HSIC
AGM 202621 May 2026 - Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 202613 May 2026 - Board urges support for director nominees and opposes majority vote proposal at annual meeting.HSIC
Proxy filing12 May 2026 - Q1 2026 delivered strong sales, margin, and EPS growth, with guidance and value initiatives reaffirmed.HSIC
Q1 20265 May 2026 - $13.2B FY2025 sales, digital transformation, and high-margin growth drive long-term value.HSIC
Corporate presentation5 May 2026